Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 6/2009

01-06-2009 | Bone Quality Seminars: Ultrastructure

Role of the small integrin-binding ligand N-linked glycoprotein (SIBLING), bone sialoprotein (BSP) in bone development and remodeling

Authors: L. Malaval, J. E. Aubin, L. Vico

Published in: Osteoporosis International | Issue 6/2009

Login to get access

Excerpt

The “small, integrin binding ligand, N-linked glycoprotein” family (SIBLINGs, [1]) group osteopontin (OPN), bone sialoprotein (BSP), dentin sialophosphoprotein (DSPP), dentin matrix protein-1 (DMP-1) and matrix extracellular glycophosphoprotein (MEPE). The genes for this family are aligned on a portion of human chromosome 4 (mouse chromosome 5), within a “Bone Gene Cluster” [2, 3] grouping other genes of bone interest. Molecular evolution studies [4, 5] suggest that SIBLINGs, along with enamelins and other proteins found in milk (caseins) and saliva (statherin), form a “Secretory Calcium binding PhosphoProteins” (SCPP) family [4], sharing as a common ancestor Hevin [6], and more precisely the long N-terminal domain that distinguishes it from the related protein SPARC (secreted protein, acidic and rich in cystein)/Osteonectin [7]. The SCPP share a flexible structure, and many contain numerous acidic aminoacid residues, which favour interactions with crystals (review in [8]). The SIBLINGs, more specifically, have acidic pI (with the exception of MEPE), and display in their sequence a proline-rich stretch (basic), consensus sites for casein-kinase, an arginine–glycine–aspartic acid (RGD) sequence-binding integrin family receptors, and (apart for BSP) one or several ASARM (acidic serine–aspartate rich MEPE associated) peptides, which have a high affinity for hydroxyapatite and appear to be potent regulators of mineralization [9, 10]. The SIBLINGs also display a high degree of post-translational modification (phosphorylation, sulfatation and/or glycosylation) which varies for a given protein in time (cellular differentiation) and space (tissue), and directly affects their biological functions (review in [11]). In bone, the SIBLINGs are expressed by cells of the osteoblast lineage, DMP-1 and MEPE being mostly restricted to osteocytes. OPN and BSP at least are also expressed by hypertrophic chondrocytes and osteoclasts. SIBLINGs are also present in multiple non-mineralized tissues, especially with secretory functions (salivary glands, kidney, [12, 13]) and by cancer cells in which they favour metastatic processes, particularly targeting bone (review in [14]). …
Literature
1.
Fisher LW, Fedarko NS (2003) Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res 44(Suppl 1):33–40PubMedCrossRef
2.
3.
MacDougall M, Simmons D, Gu TT, Dong J (2002) MEPE/OF45, a new dentin/bone matrix protein and candidate gene for dentin diseases mapping to chromosome 4q21. Connect Tissue Res 43:320–330PubMedCrossRef
4.
Kawasaki K, Suzuki T, Weiss KM (2004) Genetic basis for the evolution of vertebrate mineralized tissue. Proc Natl Acad Sci U S A 101:11356–11361PubMedCrossRef
5.
Sire JY, Delgado S, Fromentin D, Girondot M (2005) Amelogenin: lessons from evolution. Arch Oral Biol 50:205–212PubMedCrossRef
6.
Sullivan MM, Sage EH (2004) Hevin/SC1, a matricellular glycoprotein and potential tumor-suppressor of the SPARC/BM-40/Osteonectin family. Int J Biochem Cell Biol 36:991–996PubMedCrossRef
7.
Bradshaw AD, Sage EH (2001) SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 107:1049–1054PubMedCrossRef
8.
Huq NL, Cross KJ, Ung M, Reynolds EC (2005) A review of protein structure and gene organisation for proteins associated with mineralised tissue and calcium phosphate stabilisation encoded on human chromosome 4. Arch Oral Biol 50:599–609PubMedCrossRef
9.
Rowe PS (2004) The wrickkened pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med 15:264–281PubMedCrossRef
10.
Martin A, David V, Laurence JS, Schwarz PM, Lafer EM, Hedge AM, Rowe PS (2008) Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 149:1757–1772PubMedCrossRef
11.
Qin C, Baba O, Butler WT (2004) Post-translational modifications of sibling proteins and their roles in osteogenesis and dentinogenesis. Crit Rev Oral Biol Med 15:126–136PubMedCrossRef
12.
Ogbureke KU, Fisher LW (2004) Expression of SIBLINGs and their partner MMPs in salivary glands. J Dent Res 83:664–670PubMedCrossRef
13.
Ogbureke KU, Fisher LW (2005) Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs). Kidney Int 68:155–166PubMedCrossRef
14.
Bellahcene A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS (2008) Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 8:212–226PubMedCrossRef
15.
Ling Y, Rios HF, Myers ER, Lu Y, Feng JQ, Boskey AL (2005) DMP1 depletion decreases bone mineralization in vivo: an FTIR imaging analysis. J Bone Miner Res 20:2169–2177PubMedCrossRef
16.
Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE (2006) Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:1310–1315PubMedCrossRef
17.
Harris SE, Gluhak-Heinrich J, Harris MA, Yang W, Rowe PSN, Xie Y, Rios H, Zhang S, McKee MD, Bonewald LF, Feng JQ (2005) MEPE is overexpressed in osteocytes of the DMP1 (dentin matrix protein 1) null mouse, contributing to the hypophosphatemia and osteomalacia. J Bone Miner Res 20:S178–S179
18.
Gowen LC, Petersen DN, Mansolf AL, Qi H, Stock JL, Tkalcevic GT, Simmons HA, Crawford DT, Chidsey-Frink KL, Ke HZ, McNeish JD, Brown TA (2003) Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem 278:1998–2007PubMedCrossRef
19.
Quarles LD (2003) Evidence for a bone-kidney axis regulating phosphate homeostasis. J Clin Invest 112:642–646PubMed
20.
21.
Patarca R, Saavedra RA, Cantor H (1993) Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Crit Rev Immunol 13:225–246PubMed
22.
Rittling SR, Matsumoto HN, McKee MD, Nanci A, An XR, Novick KE, Kowalski AJ, Noda M, Denhardt DT (1998) Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res 13:1101–1111PubMedCrossRef
23.
Yoshitake H, Rittling SR, Denhardt DT, Noda M (1999) Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci U S A 96:8156–8160PubMedCrossRef
24.
Ishijima M, Rittling SR, Yamashita T, Tsuji K, Kurosawa H, Nifuji A, Denhardt DT, Noda M (2001) Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. J Exp Med 193:399–404PubMedCrossRef
25.
Harmey D, Johnson KA, Zelken J, Camacho NP, Hoylaerts MF, Noda M, Terkeltaub R, Millan JL (2006) Elevated skeletal osteopontin levels contribute to the hypophosphatasia phenotype in Akp2(−/−) mice. J Bone Miner Res 21:1377–1386PubMedCrossRef
26.
27.
Malaval L, Wade-Gueye NM, Boudiffa M, Fei J, Zirngibl R, Chen F, Laroche N, Roux JP, Burt-Pichat B, Duboeuf F, Boivin G, Jurdic P, Lafage-Proust MH, Amedee J, Vico L, Rossant J, Aubin JE (2008) Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. J Exp Med 205:1145–1153PubMedCrossRef
28.
Hunter GK, Goldberg HA (1994) Modulation of crystal formation by bone phosphoproteins: role of glutamic acid-rich sequences in the nucleation of hydroxyapatite by bone sialoprotein. Biochem J 302(Pt 1):175–179PubMed
29.
Gorski JP (1998) Is all bone the same? Distinctive distributions and properties of non-collagenous matrix proteins in lamellar vs. woven bone imply the existence of different underlying osteogenic mechanisms. Crit Rev Oral Biol Med 9:201–223PubMedCrossRef
30.
Gorski JP, Wang A, Lovitch D, Law D, Powell K, Midura RJ (2004) Extracellular bone acidic glycoprotein-75 defines condensed mesenchyme regions to be mineralized and localizes with bone sialoprotein during intramembranous bone formation. J Biol Chem 279:25455–25463PubMedCrossRef
31.
Midura RJ, Wang A, Lovitch D, Law D, Powell K, Gorski JP (2004) Bone acidic glycoprotein-75 delineates the extracellular sites of future bone sialoprotein accumulation and apatite nucleation in osteoblastic cultures. J Biol Chem 279:25464–25473PubMedCrossRef
32.
Gordon JA, Tye CE, Sampaio AV, Underhill TM, Hunter GK, Goldberg HA (2007) Bone sialoprotein expression enhances osteoblast differentiation and matrix mineralization in vitro. Bone 41:462–473PubMedCrossRef
33.
Raynal C, Delmas PD, Chenu C (1996) Bone sialoprotein stimulates in vitro bone resorption. Endocrinology 137:2347–2354PubMedCrossRef
34.
Valverde P, Tu Q, Chen J (2005) BSP and RANKL induce osteoclastogenesis and bone resorption synergistically. J Bone Miner Res 20:1669–1679PubMedCrossRef
Metadata
Title
Role of the small integrin-binding ligand N-linked glycoprotein (SIBLING), bone sialoprotein (BSP) in bone development and remodeling
Authors
L. Malaval
J. E. Aubin
L. Vico
Publication date
01-06-2009
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 6/2009
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-009-0869-2

Other articles of this Issue 6/2009

Osteoporosis International 6/2009 Go to the issue

Original Article

Effect of alendronate in elderly patients after low trauma hip fracture repair

Bone Quality Seminars: Ultrastructure

Bone ultrastructure: evolution during osteoporosis and aging

Original Article

RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction

Bone Quality Seminars: Ultrastructure

Bone strength and ultrastructure

Bone Quality Seminars: Ultrastructure

The Third Meeting on Bone Quality, June 2008

Review

Bone turnover markers: understanding their value in clinical trials and clinical practice